US drug major Eli Lilly has drawn up a major blueprint for enhancing research and development (R&D) activities in India, and plans to augment the spend by 25 per cent during the current financial year.
Last fiscal, the transnational spent 10 per cent of Indian turnover towards R&D. This is much higher than the domestic drug majors
